Zusammenfassung
Die nicht invasive Abklärung von Lymphknotenerkrankungen benötigt den Einsatz verschiedener technischer Geräte, um z. B. bei palpablen und sichtbaren Lymphknoten mögliche Strukturveränderungen mit dem Ultraschallgerät nachzuweisen. In der Tiefe gelegene Lymphknoten sind ebenfalls teilweise der Sonografie zugänglich. Einen Überblick können aber vor allem auch die Computertomografie (CT) und Kernspintomografie (MRT) liefern. Die Positronenemissionscomputertomografie liefert darüber hinaus Informationen zu biochemischen Gewebsveränderungen, wie Stoffwechselstörungen und Zellveränderungen an der Oberfläche (wie z.B. die Rezeptorendichte) oder im Zellinnern.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Abraham T, Schöder H. Thyroid cancer-indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med. 2011. https://doi.org/10.1053/j.semnuclmed.2010.10.006.
Afshar-Oromieh A, Avtzi E, Giesel F, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014. https://doi.org/10.1007/s00259-014-2949-6.
Agarwal V, Branstetter I, Johnson J. Indications for PET/CT in the head and neck. Otolaryngol Clin N Am. 2008. https://doi.org/10.1016/j.otc.2007.10.005.
Alessio A, Kinahan P, Cheng P, Vesselle H, Karp J. PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin N Am. 2004;42(6):1017–32. https://doi.org/10.1016/j.rcl.2004.08.001.
Ambrosini V, Nicolini S, Caroli P, et al. PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol. 2012. https://doi.org/10.1016/j.ejrad.2011.03.020.
Baum R, Kulkarni H. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy – the bad berka experience. Theranostics. 2012. https://doi.org/10.7150/thno.3645.
Baum R, Kulkarni H, Carreras C. Peptides and receptors in image-guided therapy: Theranostics for neuroendocrine neoplasms. Semin Nucl Med. 2012. https://doi.org/10.1053/j.semnuclmed.2012.01.002.
Benz M, Tchekmedyian N, Eilber F, Federman N, Czernin J, Tap W. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol. 2009. https://doi.org/10.1097/CCO.0b013e32832c95e2.
Bestic J, Peterson J, Bancroft L. Use of FDG PET in staging, restaging, and assessment of therapy response in Ewing sarcoma. RadioGraphics. 2009. https://doi.org/10.1148/rg.295095024.
Blosser G. Medical cyclotrons. Phys Today. 1993;46(10):70–3. https://doi.org/10.1063/1.881366.
Bouchelouche K, Capala J. „Image and treat“: an individualized approach to urological tumors. Curr Opin Oncol. 2010. https://doi.org/10.1097/CCO.0b013e3283373d5c.
Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970. https://doi.org/10.1097/00000658-197011000-00017.
Caroli P, Nanni C, Rubello D, Alavi A, Fanti S. Non-FDG PET in the practice of oncology. Indian J Cancer. 2010. https://doi.org/10.4103/0019-509X.62998.
Carter B, Glisson B, Truong M, Erasmus J. Small cell lung carcinoma: staging, imaging, and treatment considerations. RadioGraphics. 2014. https://doi.org/10.1148/rg.346140178.
Catana C, Wu Y, Judenhofer M, Qi J, Pichler B, Cherry S. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J Nucl Med. 2006;47(12):1968–76. doi:47/12/1968 (pii).
Cherrier-De Wilde S. Lymphoma. In: Side effects of medical cancer therapy: prevention and treatment: second edition. 2018. https://doi.org/10.1007/978-3-319-70253-7_9.
Cheson B, Fisher R, Barrington S, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. J Clin Oncol. 2014. https://doi.org/10.1200/JCO.2013.54.8800.
Coughlan M, Elstrom R. The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy. Cancer Imaging. 2014. https://doi.org/10.1186/s40644-014-0034-9.
De Winton E, Heriot A, Ng M, et al. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer. 2009. https://doi.org/10.1038/sj.bjc.6604897.
Diesen D, Skinner M. Head and neck tumors. Surg Childhood Tumors. 2016. https://doi.org/10.1007/978-3-662-48590-3_24.
Dietlein F, Kobe C, Neubauer S, et al. PSA-stratified performance of 18 F- and 68 Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2017. https://doi.org/10.2967/jnumed.116.185538.
Dietlein M, Kobe C, Kuhnert G, et al. Comparison of (18F)DCFPyL and (68Ga)Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015. https://doi.org/10.1007/s11307-015-0866-0.
Facey F, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess (Rockv). 2007. https://doi.org/10.3310/hta11440.
Friedberg E. A comprehensive catalogue of somatic mutations in cancer genomes. DNA Repair (Amst). 2010. https://doi.org/10.1016/j.dnarep.2010.01.013.
Fueger B, Yeom K, Czernin J, Sayre J, Phelps M, Allen-Auerbach M. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-hodgkin’s lymphoma. Mol Imaging Biol. 2009;11(4):269–74. https://doi.org/10.1007/s11307-009-0200-9.
de Geus-Oei L-F, Vriens D, van Laarhoven H, van der Graaf W, Oyen W. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med. 2009. https://doi.org/10.2967/jnumed.108.057224.
Giesel F, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-016-3573-4.
Goto A, Tachikawa T, Jongen Y, Schillo M. Cyclotrons. Compr Biomed Phys. 2014;8:179–95. https://doi.org/10.1016/B978-0-444-53632-7.00612-2.
Halasz L, Jacene H, Catalano P, et al. Combined modality treatment for PET-positive non-hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012. https://doi.org/10.1016/j.ijrobp.2012.01.060.
Hutchings M, Barrington S. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009. https://doi.org/10.2967/jnumed.108.057190.
de Jong M, Mayo S, Pulitano C, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg. 2009.
Juweid M, Stroobants S, Hoekstra O, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol. 2007. https://doi.org/10.1200/JCO.2006.08.2305.
Kauhanen S, Schalin-Jantti C, Seppanen M, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011. https://doi.org/10.2967/jnumed.111.094771.
Kelkar S, Reineke T. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011. https://doi.org/10.1021/bc200151q.
Koopmans K, de Groot J, Plukker J, et al. 18F-Dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008. https://doi.org/10.2967/jnumed.107.047720.
Kowalski J, Henze M, Schuhmacher J, Mäcke H, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using (68Ga)-DOTA-D Phe1-Tyr3- octreotidein comparison to (111In)-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003. https://doi.org/10.1016/S1536-1632(03)00038-6.
Kwee T, Kwee R, Nievelstein R. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008. https://doi.org/10.1182/blood-2007-07-101899.
Kwekkeboom D, Kam BL, Van Essen M, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010. https://doi.org/10.1677/ERC-09-0078.
Love C, Tomas M, Tronco G, Palestro C. FDG PET of infection. Radiographics. 2005. https://doi.org/10.1148/rg.255045122.
Marcus C, Whitworth P, Surasi D, Pai S, Subramaniam R. PET/CT in the management of thyroid cancers. Am J Roentgenol. 2014. https://doi.org/10.2214/AJR.13.11673.
Matasar M, Zelenetz A. Overview of lymphoma diagnosis and management. Radiol Clin N Am. 2008. https://doi.org/10.1016/j.rcl.2008.03.005.
Meller J, Sahlmann C, Scheel A. PET and PET/CT in Fever of 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007. https://doi.org/10.1530/rep.1.00500.
Miederer M, Seidl S, Buck A, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging. 2009. https://doi.org/10.1007/s00259-008-0944-5.
Nakagawa T, Yamada M, Suzuki Y. 18F-FDG uptake in reactive neck lymph nodes of oral cancer: relationship to lymphoid follicles. J Nucl Med. 2008;49(7):1053–9. https://doi.org/10.2967/jnumed.107.049718.
Nathan C, Ekshyyan O, Anandharaj A. Head and neck cancers. In: Translation and its regulation in cancer biology and medicine. 2014. https://doi.org/10.1007/978-94-017-9078-9_25.
Non Hodgkin’s Lymphoma Project Classification. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood. 1997. https://doi.org/10.3322/canjclin.46.1.5.
Pauwels J, Ribeiro J, Stoot J, McCready V, Bourguignon M, Mazière B. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25(4):317–22. https://doi.org/10.1016/S0969-8051(97)00226-6.
Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016. https://doi.org/10.1016/j.eururo.2016.06.021.
Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007. https://doi.org/10.1016/j.athoracsur.2007.02.093.
Pichler J, Kolb A, Nagele T, Schlemmer H-P. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010;51(3):333–6. https://doi.org/10.2967/jnumed.109.061853.
Potter M, Newport E, Morten K. The Warburg effect: 80 years on. Biochem Soc Trans. 2016. https://doi.org/10.1042/BST20160094.
Quartuccio N, Fox J, Kuk D, et al. Pediatric bone sarcoma: diagnostic performance of 18 F-FDG PET/CT versus conventional imaging for initial staging and follow-up. Am J Roentgenol. 2015. https://doi.org/10.2214/AJR.14.12932.
Queiroz M, Huellner M. PET/MR in cancers of the head and neck. Semin Nucl Med. 2015. https://doi.org/10.1053/j.semnuclmed.2014.12.005.
Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015. https://doi.org/10.1056/NEJMoa1408648.
Robbins R, Wan Q, Grewal R, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-( 18F)fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006. https://doi.org/10.1210/jc.2005-1534.
Roberge D, Vakilian S, Alabed Y, Turcotte R, Freeman C, Hickeson M. FDG PET/CT in initial staging of adult soft-tissue sarcoma. Sarcoma. 2012. https://doi.org/10.1155/2012/960194.
Rota Kops E, Qin P, Mueller-Veggian M, Herzog H. Attenuation correction of PET scanning based on MRT-images. In: Proceedings of IEEE nuclear science symposium and medical imaging conference. 2006: Abstract only. San Diego, California. ISBN: 9781424405619.
Specht L. 2-(18F)Fluoro-2-Deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol. 2007. https://doi.org/10.1016/j.semradonc.2007.02.005.
Talbot N, Petegnief Y, de Beco V, Nataf V, Balard M. Basics of PET and PET/CT imaging: instrumentation and radiopharmaceuticals for clinical diagnosis. Presse Med 2006;35(9 Pt 2):1331-1337.
Travis W, Brambilla E, Nicholson A, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015. https://doi.org/10.1097/JTO.0000000000000630.
Treglia G, Castaldi P, Villani M, et al. Comparison of18F-DOPA,18F-FDG and68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012. https://doi.org/10.1007/s00259-011-2031-6.
Trotter S, Sroa N, Winkelmann R, Olencki T, Bechtel M. A global review of melanoma follow-up guidelines. J Clin Aesthet Dermatol. 2013;6(9):18–26.
Velikyan I, Sundin A, Sorensen J, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014. https://doi.org/10.2967/jnumed.113.126177.
Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol. 2010;73(3):461–9. https://doi.org/10.1016/j.ejrad.2009.12.022.
Wagner H. Non-small cell lung cancer. In: Clinical radiation oncology: third edition. 2011. https://doi.org/10.1016/B978-1-4377-1637-5.00042-0.
Warburg O. The metabolism of tumors in the body. J Gen Physiol. 1927. https://doi.org/10.1085/jgp.8.6.519.
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14. https://doi.org/10.1126/science.123.3191.309.
Xing Y, Bronstein Y, Ross M, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011. https://doi.org/10.1093/jnci/djq455.
Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2014. https://doi.org/10.1177/0284185113496679.
Yu S. Review of F-FDG synthesis and quality control. Biomed Imaging Interv J. 2006;2(4):e57. https://doi.org/10.2349/biij.2.4.e57, https://doi.org/10.1007/s11605-009-1050-0.
Zeller K, Zhao X, Lee C, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci. 2006. https://doi.org/10.1073/pnas.0604129103.
Zhuang H, Yu J, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin N Am. 2005. https://doi.org/10.1016/j.rcl.2004.07.005.
Zinzani P, Stefoni V, Tani M, et al. Role of (18F)fluorodeoxyglucose positron emission tomografy scan in the follow-up of lymphoma. J Clin Oncol. 2009. https://doi.org/10.1200/JCO.2008.16.1513.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature
About this chapter
Cite this chapter
Reuland, P. (2021). Positronenemissionscomputertomografie (PET); Detektion pathologischer Lymphknoten mit Hilfe der Positronenemissionscomputertomografie. In: Brauer, W.J. (eds) Bildgebung Lymphologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62530-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-662-62530-9_15
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-62529-3
Online ISBN: 978-3-662-62530-9
eBook Packages: Medicine (German Language)